Literature DB >> 18095100

Epithelioid glioblastoma: a case report.

Jiro Akimoto1, Hiroaki Namatame, Jo Haraoka, Motoshige Kudo.   

Abstract

A 43-year-old woman who had undergone breast cancer surgery 1 year previously complained of headache and nausea. Her brain computed tomography (CT) scan and magnetic resonance imaging (MRI) showed a well-circumscribed, heterogeneously enhanced tumor in the right thalamus. She underwent gross total resection of the tumor followed by radiochemotherapy, and her clinical course was uneventful after surgery. Histological examination revealed a moderate number of tumor cells with fine bipolar processes in a mucoid matrix, which suggested pilocytic astrocytoma. The tumor was associated with microvascular proliferation but did not show significant mitosis or necrosis. In some areas, it had an epithelioid appearance, with ribbon-like, cribriform, and pseudoglandular patterns involving cuboid-shaped cells showing nuclear atypia and mitotic figures. Immunohistochemically, the tumor cells were positive for glial fibrillary acidic protein (GFAP) and vimentin in the area resembling pilocytic astrocytoma, but in the epithelioid area they were negative for GFAP and vimentin as well as for breast cancer markers, including AE1/AE3. The proliferating potential, represented by the MIB-1 labeling index, was high (82.5%) in the area of epithelioid appearance, compared to only 3% in the area of pilocytic astrocytoma-like appearance. As a rare histoarchitectural variant of glioblastoma, the epithelioid pattern may represent a very primitive tumor cell phenotype. Typically, this pattern is characterized by well-circumscribed masses, although its clinical significance is unknown.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 18095100     DOI: 10.1007/s10014-005-0173-6

Source DB:  PubMed          Journal:  Brain Tumor Pathol        ISSN: 1433-7398            Impact factor:   3.298


  8 in total

1.  Epithelial and pseudoepithelial differentiation in glioblastoma and gliosarcoma: a comparative morphologic and molecular genetic study.

Authors:  Fausto J Rodriguez; Bernd W Scheithauer; Caterina Giannini; Sandra C Bryant; Robert B Jenkins
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

2.  BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.

Authors:  Bette K Kleinschmidt-DeMasters; Dara L Aisner; Nicholas K Foreman
Journal:  Am J Surg Pathol       Date:  2015-04       Impact factor: 6.394

Review 3.  Glioma Subclassifications and Their Clinical Significance.

Authors:  Ricky Chen; Matthew Smith-Cohn; Adam L Cohen; Howard Colman
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

4.  Epithelioid GBMs show a high percentage of BRAF V600E mutation.

Authors:  Bette Kay Kleinschmidt-DeMasters; Dara L Aisner; Diane K Birks; Nicholas K Foreman
Journal:  Am J Surg Pathol       Date:  2013-05       Impact factor: 6.394

5.  Composite pleomorphic xanthoastrocytoma-epithelioid glioneuronal tumor with BRAF V600E mutation - report of three cases.

Authors:  Dara L Aisner; Kathy L Newell; Ania G Pollack; Bette K Kleinschmidt-Demasters; Gary K Steinberg; Lawrence T Smyth; Hannes Vogel
Journal:  Clin Neuropathol       Date:  2014 Mar-Apr       Impact factor: 1.368

6.  Carbohydrate Microarrays Identify Blood Group Precursor Cryptic Epitopes as Potential Immunological Targets of Breast Cancer.

Authors:  Denong Wang; Jin Tang; Shaoyi Liu; Jiaoti Huang
Journal:  J Immunol Res       Date:  2015-10-11       Impact factor: 4.818

7.  Cell surface area and membrane folding in glioblastoma cell lines differing in PTEN and p53 status.

Authors:  Simon Memmel; Vladimir L Sukhorukov; Marcus Höring; Katherine Westerling; Vanessa Fiedler; Astrid Katzer; Georg Krohne; Michael Flentje; Cholpon S Djuzenova
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

8.  BRAF V600E mutation and BRAF VE1 immunoexpression profiles in different types of glioblastoma.

Authors:  Zeynep Tosuner; Melin Özgün Geçer; Mustafa Aziz Hatiboğlu; Anas Abdallah; Seval Turna
Journal:  Oncol Lett       Date:  2018-06-06       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.